Symbols / BMEA $1.50 -0.66% Biomea Fusion, Inc.
BMEA Chart
About
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 108.45M |
| Enterprise Value | 57.12M | Income | -61.80M | Sales | — |
| Book/sh | 0.41 | Cash/sh | 0.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | 41 | IPO | — |
| P/E | — | Forward P/E | -1.41 | PEG | — |
| P/S | — | P/B | 3.67 | P/C | — |
| EV/EBITDA | -0.71 | EV/Sales | — | Quick Ratio | 5.03 |
| Current Ratio | 5.23 | Debt/Eq | 5.38 | LT Debt/Eq | — |
| EPS (ttm) | -1.18 | EPS next Y | -1.06 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-04 | ROA | -73.38% |
| ROE | -152.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 72.30M |
| Shs Float | 67.44M | Short Float | 19.98% | Short Ratio | 14.13 |
| Short Interest | — | 52W High | 3.08 | 52W Low | 0.87 |
| Beta | -0.27 | Avg Volume | 1.25M | Volume | 143.33K |
| Target Price | $7.17 | Recom | Buy | Prev Close | $1.51 |
| Price | $1.50 | Change | -0.66% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | Citigroup | Buy → Buy | $7 |
| 2026-03-25 | main | D. Boral Capital | Buy → Buy | $12 |
| 2026-01-13 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-11-10 | main | Citigroup | Buy → Buy | $6 |
| 2025-11-05 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-10-27 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-10-03 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-28 | init | Jefferies | — → Buy | $5 |
| 2025-08-11 | main | Citigroup | Buy → Buy | $7 |
| 2025-08-06 | main | Scotiabank | Sector Outperform → Sector Outperform | $10 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-21 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-16 | main | Citigroup | Buy → Buy | $9 |
| 2025-06-24 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-18 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-13 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-06 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-06 | main | HC Wainwright & Co. | Buy → Buy | $18 |
- Biomea lines up four diabetes and obesity readouts before cash runs out - Stock Titan ue, 24 Mar 2026 07
- Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat Mon, 06 Apr 2026 06
- $BMEA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative hu, 15 Jan 2026 08
- BMEA Jan 2027 7.500 call (BMEA270115C00007500) stock price, news, quote and history - Yahoo Finance Singapore Sun, 05 Apr 2026 10
- Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan Fri, 03 Apr 2026 20
- Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat hu, 12 Mar 2026 07
- BMEA Jan 2027 3.000 call (BMEA270115C00003000) stock price, news, quote and history - Yahoo Finance Singapore Sun, 05 Apr 2026 09
- Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan Fri, 03 Apr 2026 20
- Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance Sat, 24 Jan 2026 08
- Insider Purchase: Interim CEO of $BMEA Buys 100,000 Shares | BMEA Stock News - Quiver Quantitative hu, 04 Dec 2025 08
- If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan Sun, 22 Mar 2026 10
- BMEA Jul 2026 0.500 call (BMEA260717C00000500) Stock Historical Prices & Data - Yahoo! Finance Canada hu, 02 Apr 2026 12
- Clinical-stage diabetes and obesity firm Biomea Fusion hits 3 investor events - Stock Titan hu, 19 Feb 2026 08
- BMEA Oct 2026 2.500 put (BMEA261016P00002500) interactive stock chart - Yahoo Finance UK Wed, 01 Apr 2026 12
- Patients failing standard diabetes drugs enter 2 Biomea studies - Stock Titan ue, 31 Mar 2026 11
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
81.31
-43.56%
|
144.07
+14.22%
|
126.14
+50.82%
|
83.63
|
| Research And Development |
|
61.98
-47.51%
|
118.08
+15.15%
|
102.55
+63.52%
|
62.71
|
| Selling General And Administration |
|
19.33
-25.62%
|
25.98
+10.16%
|
23.59
+12.75%
|
20.92
|
| General And Administrative Expense |
|
19.33
-25.62%
|
25.98
+10.16%
|
23.59
+12.75%
|
20.92
|
| Other Gand A |
|
19.33
-25.62%
|
25.98
+10.16%
|
23.59
+12.75%
|
20.92
|
| Total Expenses |
|
81.31
-43.56%
|
144.07
+14.22%
|
126.14
+50.82%
|
83.63
|
| Operating Income |
|
-81.31
+43.56%
|
-144.07
-14.22%
|
-126.14
-50.82%
|
-83.63
|
| Total Operating Income As Reported |
|
-83.51
+42.03%
|
-144.07
-14.22%
|
-126.14
-50.82%
|
-83.63
|
| EBITDA |
|
-79.90
+43.86%
|
-142.32
-14.20%
|
-124.62
-50.25%
|
-82.94
|
| Normalized EBITDA |
|
-97.55
+31.46%
|
-142.32
-14.20%
|
-124.62
-50.25%
|
-82.94
|
| Reconciled Depreciation |
|
1.41
-19.39%
|
1.75
+15.38%
|
1.51
+119.25%
|
0.69
|
| EBIT |
|
-81.31
+43.56%
|
-144.07
-14.22%
|
-126.14
-50.82%
|
-83.63
|
| Total Unusual Items |
|
17.65
|
0.00
|
0.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
17.65
|
0.00
|
0.00
|
—
|
| Special Income Charges |
|
-2.21
|
0.00
|
0.00
|
—
|
| Impairment Of Capital Assets |
|
2.21
|
0.00
|
0.00
|
—
|
| Net Income |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Pretax Income |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Net Non Operating Interest Income Expense |
|
1.86
-67.08%
|
5.64
-36.44%
|
8.88
+391.69%
|
1.81
|
| Net Interest Income |
|
1.86
-67.08%
|
5.64
-36.44%
|
8.88
+391.69%
|
1.81
|
| Interest Income Non Operating |
|
1.86
-67.08%
|
5.64
-36.44%
|
8.88
+391.69%
|
1.81
|
| Interest Income |
|
1.86
-67.08%
|
5.64
-36.44%
|
8.88
+391.69%
|
1.81
|
| Other Income Expense |
|
17.65
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
19.86
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Net Income From Continuing Operation Net Minority Interest |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Net Income From Continuing And Discontinued Operation |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Net Income Continuous Operations |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Normalized Income |
|
-79.45
+42.61%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Net Income Common Stockholders |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Diluted EPS |
|
—
|
-3.83
-11.34%
|
-3.44
-22.86%
|
-2.80
|
| Basic EPS |
|
—
|
-3.83
-11.34%
|
-3.44
-22.86%
|
-2.80
|
| Basic Average Shares |
|
—
|
36.11
+5.86%
|
34.11
+16.52%
|
29.27
|
| Diluted Average Shares |
|
—
|
36.11
+5.86%
|
34.11
+16.52%
|
29.27
|
| Diluted NI Availto Com Stockholders |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
58.57
-26.73%
|
79.94
-60.02%
|
199.93
+54.61%
|
129.31
|
| Current Assets |
|
58.05
-15.05%
|
68.33
-61.86%
|
179.18
+52.08%
|
117.82
|
| Cash Cash Equivalents And Short Term Investments |
|
55.81
-4.23%
|
58.28
-67.05%
|
176.87
+56.45%
|
113.05
|
| Cash And Cash Equivalents |
|
55.81
-4.23%
|
58.28
-67.05%
|
176.87
+58.06%
|
111.90
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
1.15
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
2.24
-77.74%
|
10.05
+334.25%
|
2.31
-51.47%
|
4.77
|
| Total Non Current Assets |
|
0.52
-95.50%
|
11.61
-44.06%
|
20.75
+80.59%
|
11.49
|
| Net PPE |
|
0.15
-98.56%
|
10.62
-28.61%
|
14.87
+86.10%
|
7.99
|
| Gross PPE |
|
1.16
-92.15%
|
14.80
-14.49%
|
17.30
+94.25%
|
8.91
|
| Accumulated Depreciation |
|
-1.01
+75.86%
|
-4.18
-71.90%
|
-2.43
-165.39%
|
-0.92
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.58
+0.00%
|
0.58
+7.24%
|
0.54
+18.46%
|
0.46
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
0.00
-99.87%
|
3.17
|
| Other Properties |
|
0.10
-99.05%
|
10.78
-20.54%
|
13.57
+202.68%
|
4.48
|
| Leases |
|
0.48
-85.98%
|
3.44
+7.64%
|
3.19
+298.88%
|
0.80
|
| Investments And Advances |
|
—
|
—
|
0.00
|
0.00
|
| Other Non Current Assets |
|
0.37
-62.65%
|
0.99
-83.18%
|
5.87
+67.99%
|
3.50
|
| Total Liabilities Net Minority Interest |
|
29.02
+2.31%
|
28.36
-7.58%
|
30.69
+47.78%
|
20.77
|
| Current Liabilities |
|
11.10
-48.78%
|
21.67
-5.19%
|
22.86
+19.68%
|
19.10
|
| Payables And Accrued Expenses |
|
9.47
-51.16%
|
19.39
-4.01%
|
20.20
+13.20%
|
17.85
|
| Payables |
|
3.23
-75.00%
|
12.93
+88.76%
|
6.85
+0.37%
|
6.83
|
| Accounts Payable |
|
3.23
-75.00%
|
12.93
+88.76%
|
6.85
+0.37%
|
6.83
|
| Current Accrued Expenses |
|
6.24
-3.42%
|
6.46
-51.62%
|
13.35
+21.14%
|
11.02
|
| Current Debt And Capital Lease Obligation |
|
1.46
-29.73%
|
2.08
-15.69%
|
2.47
+299.03%
|
0.62
|
| Current Capital Lease Obligation |
|
1.46
-29.73%
|
2.08
-15.69%
|
2.47
+299.03%
|
0.62
|
| Other Current Liabilities |
|
0.17
-16.75%
|
0.20
+5.73%
|
0.19
-69.81%
|
0.64
|
| Total Non Current Liabilities Net Minority Interest |
|
17.92
+167.77%
|
6.69
-14.53%
|
7.83
+369.71%
|
1.67
|
| Long Term Debt And Capital Lease Obligation |
|
0.13
-98.09%
|
6.69
-14.53%
|
7.83
+369.71%
|
1.67
|
| Long Term Capital Lease Obligation |
|
0.13
-98.09%
|
6.69
-14.53%
|
7.83
+369.71%
|
1.67
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Common Stock Equity |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Capital Stock |
|
0.01
+75.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| Common Stock |
|
0.01
+75.00%
|
0.00
+0.00%
|
0.00
+33.33%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
72.30
+99.11%
|
36.31
+1.24%
|
35.87
+21.33%
|
29.56
|
| Ordinary Shares Number |
|
72.30
+99.11%
|
36.31
+1.24%
|
35.87
+21.33%
|
29.56
|
| Additional Paid In Capital |
|
478.59
+9.06%
|
438.82
+4.97%
|
418.06
+74.11%
|
240.11
|
| Retained Earnings |
|
-449.05
-15.96%
|
-387.25
-55.63%
|
-248.82
-89.12%
|
-131.57
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-0.00
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-0.00
|
| Total Equity Gross Minority Interest |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Total Capitalization |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Working Capital |
|
46.95
+0.62%
|
46.66
-70.15%
|
156.32
+58.35%
|
98.72
|
| Invested Capital |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Total Debt |
|
1.59
-81.88%
|
8.77
-14.81%
|
10.30
+350.59%
|
2.29
|
| Capital Lease Obligations |
|
1.59
-81.88%
|
8.77
-14.81%
|
10.30
+350.59%
|
2.29
|
| Net Tangible Assets |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Tangible Book Value |
|
29.55
-42.70%
|
51.57
-69.53%
|
169.24
+55.92%
|
108.54
|
| Derivative Product Liabilities |
|
17.79
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-70.37
+41.31%
|
-119.89
-24.12%
|
-96.59
-54.75%
|
-62.42
|
| Cash Flow From Continuing Operating Activities |
|
-70.37
+41.31%
|
-119.89
-24.12%
|
-96.59
-54.75%
|
-62.42
|
| Net Income From Continuing Operations |
|
-61.80
+55.36%
|
-138.43
-18.06%
|
-117.25
-43.29%
|
-81.83
|
| Depreciation Amortization Depletion |
|
1.41
-19.39%
|
1.75
+15.38%
|
1.51
+119.25%
|
0.69
|
| Depreciation |
|
1.41
-19.39%
|
1.75
+15.38%
|
1.51
+119.25%
|
0.69
|
| Depreciation And Amortization |
|
1.41
-19.39%
|
1.75
+15.38%
|
1.51
+119.25%
|
0.69
|
| Other Non Cash Items |
|
1.85
-34.92%
|
2.84
+5.66%
|
2.69
+370.40%
|
0.57
|
| Stock Based Compensation |
|
9.52
-50.14%
|
19.09
+35.12%
|
14.13
+36.72%
|
10.34
|
| Asset Impairment Charge |
|
2.21
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
-19.86
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-19.86
|
—
|
—
|
—
|
| Change In Working Capital |
|
-3.70
+28.17%
|
-5.15
-320.94%
|
2.33
-69.62%
|
7.67
|
| Change In Prepaid Assets |
|
7.82
+201.00%
|
-7.74
-412.27%
|
2.48
+243.65%
|
-1.73
|
| Change In Payables And Accrued Expense |
|
-9.96
-1155.36%
|
-0.79
-117.83%
|
4.45
-62.54%
|
11.87
|
| Change In Accrued Expense |
|
-0.26
+96.29%
|
-6.88
-464.85%
|
1.89
-78.84%
|
8.91
|
| Change In Payable |
|
-9.70
-259.33%
|
6.09
+137.63%
|
2.56
-13.45%
|
2.96
|
| Change In Account Payable |
|
-9.70
-259.33%
|
6.09
+137.63%
|
2.56
-13.45%
|
2.96
|
| Change In Other Current Assets |
|
0.62
-87.33%
|
4.88
+307.12%
|
-2.36
-23.13%
|
-1.92
|
| Change In Other Current Liabilities |
|
-2.18
-45.04%
|
-1.50
+32.93%
|
-2.24
-296.11%
|
-0.56
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.36
+83.69%
|
-2.22
-108.12%
|
27.34
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.36
+83.69%
|
-2.22
-108.12%
|
27.34
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.36
+89.26%
|
-3.37
-227.18%
|
-1.03
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.36
+89.26%
|
-3.37
-227.18%
|
-1.03
|
| Capital Expenditure |
|
—
|
-0.36
+89.26%
|
-3.37
-227.18%
|
-1.03
|
| Net Investment Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
1.15
-95.95%
|
28.37
|
| Purchase Of Investment |
|
—
|
—
|
0.00
|
0.00
|
| Sale Of Investment |
|
0.00
|
0.00
-100.00%
|
1.15
-95.95%
|
28.37
|
| Financing Cash Flow |
|
67.90
+3970.98%
|
1.67
-98.98%
|
163.80
+13120.18%
|
1.24
|
| Cash Flow From Continuing Financing Activities |
|
67.90
+3970.98%
|
1.67
-98.98%
|
163.80
+13120.18%
|
1.24
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
67.75
|
0.00
-100.00%
|
161.80
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.16
-90.47%
|
1.67
-16.39%
|
2.00
+61.02%
|
1.24
|
| Changes In Cash |
|
-2.47
+97.92%
|
-118.59
-282.48%
|
64.99
+292.06%
|
-33.84
|
| Beginning Cash Position |
|
58.65
-66.91%
|
177.24
+57.89%
|
112.25
-23.16%
|
146.09
|
| End Cash Position |
|
56.18
-4.21%
|
58.65
-66.91%
|
177.24
+57.89%
|
112.25
|
| Free Cash Flow |
|
-70.37
+41.48%
|
-120.26
-20.30%
|
-99.96
-57.55%
|
-63.45
|
| Amortization Of Securities |
|
0.00
|
0.00
-100.00%
|
0.00
-99.31%
|
0.14
|
| Common Stock Issuance |
|
67.75
|
0.00
-100.00%
|
161.80
|
0.00
|
| Issuance Of Capital Stock |
|
67.75
|
0.00
-100.00%
|
161.80
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-03 View
- 10-K2026-03-24 View
- 8-K2026-03-24 View
- 8-K2026-02-25 View
- 8-K2026-01-14 View
- 42025-12-15 View
- 42025-12-04 View
- 42025-12-02 View
- 10-Q2025-11-04 View
- 8-K2025-11-04 View
- 8-K2025-10-07 View
- 8-K2025-10-06 View
- 42025-08-13 View
- 42025-08-13 View
- 10-Q2025-08-05 View
- 8-K2025-08-05 View
- 42025-08-01 View
- 42025-07-24 View
- 8-K2025-07-24 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|